Interdisciplinary neuro-oncology. Part 2: systemic therapy of primary brain tumors

被引:0
作者
Tabatabai, G. [1 ]
Hattingen, E. [2 ]
Schlegel, J. [3 ]
Stummer, W. [4 ]
Schlegel, U. [5 ]
机构
[1] Univ Klinikum Tubingen, Interdisziplinare Sekt Neuroonkol, Klin Neurochirurg, Zentrum Neurol, Tubingen, Germany
[2] Univ Frankfurt Klinikum, Inst Neuroradiol, Frankfurt, Germany
[3] Tech Univ Munich, Sekt Neuropathol, Inst Allgemeine Pathol & Pathol Anat, D-80290 Munich, Germany
[4] Univ Klinikum Munster, Neurochirurg Klin, Munster, Germany
[5] Klinikum Ruhruniv Bochum, Knappschaftskrankenhaus, Neurol Univ Klin, D-44892 Bochum, Germany
来源
NERVENARZT | 2014年 / 85卷 / 08期
关键词
Radiation therapy; Temozolomide; Bevacizumab; Lomustine; Survival; NEWLY-DIAGNOSED GLIOBLASTOMA; RANDOMIZED PHASE-III; ADJUVANT TEMOZOLOMIDE; RADIATION-THERAPY; RADIOTHERAPY; CONCOMITANT; BEVACIZUMAB; MUTATIONS; SUBGROUPS; TRIAL;
D O I
10.1007/s00115-014-4122-7
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
By combining the expertise of clinical neuroscience, the aim of neuro-oncology is to optimize diagnostic planning and therapy of primary brain tumors in an interdisciplinary setting together with radio-oncology and medical oncology. High-end imaging frequently allows brain tumors to be diagnosed preoperatively with respect to tumor entity and even tumor malignancy grade. Moreover, neuroimaging is indispensable for guidance of biopsy resection and monitoring of therapy. Surgical resection of intracranial lesions with preservation of neurological function has become dramatically more extensive. Tools to achieve this goal are, for example neuronavigation, functional magnetic resonance imaging (fMRI), tractography, intraoperative cortical stimulation and precise intraoperative definition of tumor margins by virtue of various techniques. In addition to classical histopathological diagnosis and tumor classification, modern neuropathology is supplemented by molecular characterization of brain tumors in order to provide clinicians with prognostic and predictive (of therapy) markers, such as codeletion of chromosomes 1p and 19q in anaplastic gliomas and O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation in glioblastomas. Although this is not yet individualized tumor therapy, the increasingly more detailed analysis of the molecular pathogenesis of an individual glioma will eventually lead to specific pharmacological blockade of disturbed intracellular pathways in individual patients. This article gives an overview of the state of the art of interdisciplinary neuro-oncology whereby part 1 deals with the diagnostics and surgical therapy of primary brain tumors and part 2 describes the medical therapy of primary brain tumors.
引用
收藏
页码:976 / 981
页数:6
相关论文
empty
未找到相关数据